Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank lessened its holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 50.0% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 7,809 shares of the company’s stock after selling 7,809 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Zentalis Pharmaceuticals were worth $32,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the business. Quest Partners LLC acquired a new position in Zentalis Pharmaceuticals during the 4th quarter worth about $38,000. SG Americas Securities LLC acquired a new position in Zentalis Pharmaceuticals during the 2nd quarter worth about $58,000. 49 Wealth Management LLC acquired a new position in Zentalis Pharmaceuticals during the 1st quarter worth about $172,000. Kennedy Capital Management LLC acquired a new position in Zentalis Pharmaceuticals during the 1st quarter worth about $189,000. Finally, Carson Advisory Inc. acquired a new position in Zentalis Pharmaceuticals during the 1st quarter worth about $201,000.

Analyst Ratings Changes

Several research firms recently issued reports on ZNTL. Wells Fargo & Company lowered Zentalis Pharmaceuticals from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $29.00 to $9.00 in a research note on Tuesday, June 18th. Wedbush raised Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 target price on the stock in a research note on Monday, August 12th. UBS Group downgraded Zentalis Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the stock from $28.00 to $5.00 in a report on Thursday, June 20th. Jefferies Financial Group restated a “hold” rating and set a $6.00 price target (down previously from $42.00) on shares of Zentalis Pharmaceuticals in a report on Tuesday, June 18th. Finally, Morgan Stanley restated an “equal weight” rating and set a $8.00 price target (down previously from $38.00) on shares of Zentalis Pharmaceuticals in a report on Tuesday, June 18th. Seven equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, Zentalis Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $11.33.

Zentalis Pharmaceuticals Stock Performance

ZNTL opened at $3.27 on Wednesday. Zentalis Pharmaceuticals, Inc. has a one year low of $2.83 and a one year high of $25.33. The company has a market cap of $232.26 million, a P/E ratio of -0.98 and a beta of 1.70. The business’s 50-day simple moving average is $3.57 and its 200-day simple moving average is $8.94.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings data on Friday, August 9th. The company reported ($1.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.40). During the same quarter last year, the firm posted ($1.85) earnings per share. As a group, analysts predict that Zentalis Pharmaceuticals, Inc. will post -2.95 earnings per share for the current fiscal year.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.